Quantum Biopharma (NASDAQ:QNTM) Upgraded to “Hold” at Wall Street Zen

Quantum Biopharma (NASDAQ:QNTM) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Quantum Biopharma in a research report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Quantum Biopharma presently has an average rating of “Sell”.

Quantum Biopharma Price Performance

Shares of NASDAQ QNTM opened at $4.77 on Friday. Quantum Biopharma has a 1-year low of $2.07 and a 1-year high of $38.25. The business’s fifty day moving average price is $3.96 and its two-hundred day moving average price is $8.85. The firm has a market capitalization of $18.22 million, a PE ratio of -0.55 and a beta of 0.32.

Quantum Biopharma (NASDAQ:QNTM) last announced its quarterly earnings results on Thursday, March 26th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.49). Equities research analysts expect that Quantum Biopharma will post -3.27 earnings per share for the current fiscal year.

Institutional Trading of Quantum Biopharma

A number of institutional investors have recently made changes to their positions in the stock. Steward Partners Investment Advisory LLC acquired a new position in shares of Quantum Biopharma during the second quarter valued at approximately $63,000. Virtu Financial LLC bought a new stake in Quantum Biopharma during the fourth quarter worth approximately $76,000. Finally, Jane Street Group LLC acquired a new stake in Quantum Biopharma in the fourth quarter worth approximately $80,000. 1.24% of the stock is owned by institutional investors and hedge funds.

Quantum Biopharma Company Profile

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.